ETC-206 (D3-003)

D3-003 is a Phase I clinical trial to evaluate the safety, tolerability, blood levels, and target engagement of ETC-206, a novel cancer drug candidate which could be used for the treatment of blood cancers. The three main groups of blood cancer are leukaemia, lymphoma and myeloma, two of which (leukaemia and lymphoma) are among the 10 types of cancer with the highest mortality rates in Singapore.

ETC-206 is the first Mnk-inhibitor capable of targeting the enzyme in liquid cancers to suppress cancer proliferation and prevent cancer progression. This offers a therapeutic strategy that could potentially lower the mortality rates caused by blood cancers.

A uniquely “Made in Singapore” discovery, ETC-206 was discovered and developed through a collaboration between A*STAR’s Experimental Therapeutics Centre (ETC), the Drug Discovery and Development (D3) unit, and Duke-National University of Singapore Medical School (Duke-NUS), a partnership which began in May 2010.

The study team also comprised
• a clinical site at the SingHealth Investigational Medicine Unit (IMU),
located at the Singapore General Hospital (SGH) in Singapore
• an academic CRO at Singapore Clinical Research Institute (SCRI)
• a central lab, Quest Laboratories from Singapore
• three vendors from France (SGS, Phinc and CEMO for PD marker and
PK data analysis)
• a vendor from US (ERT, ECG monitoring)
• a vendor from India (CDISC submission)

The drug was developed through a complex series of laboratory and clinical research with the aim of identifying better treatment options for our patients. The study showcases the capabilities and strong partnerships between Singapore research teams, evident in their creation of a new milestone in cancer drug development.

SCRI is coordinating the clinical research operations led by D3. SCRI’s coordination services range from biostatistics, research monitoring, data and project management, pharmacovigilance to research informatics. Phase 1 trials will evaluate the safety, tolerability, blood levels, and target engagement of ETC-206 in up to 17 healthy volunteers.